A 58-year-old man with a 20-year history of smoking presents with a 2-week history of hemoptysis and progressive dyspnea. On examination, he has reduced air entry on the right side. Chest X-ray shows a 4 cm irregular opacity in the right upper lobe with hilar lymphadenopathy. Sputum cytology is negative for malignancy. What is the most appropriate next imaging modality to characterize the lesion and assess for metastases?

Explanation

## Clinical Presentation A smoker with hemoptysis, dyspnea, and a suspicious lung lesion (irregular opacity, hilar lymphadenopathy) raises strong suspicion for **lung cancer**. Negative sputum cytology does not exclude malignancy. ## Imaging Strategy for Suspected Lung Cancer **Key Point:** High-resolution CT (HRCT) chest with contrast is the imaging modality of choice for initial characterization of lung lesions and staging of suspected lung cancer. ### Why HRCT is First-Line | Feature | HRCT + Contrast | PET-CT | Chest MRI | Repeat CXR | |---------|-----------------|--------|-----------|------------| | **Lesion characterization** | Excellent (density, margins, cavitation) | Functional only (metabolic activity) | Limited | Poor | | **Mediastinal/hilar assessment** | Excellent | Good but limited spatial detail | Poor | Poor | | **Pulmonary nodule detection** | Excellent (detects nodes <5 mm) | Limited sensitivity for small nodes | Poor | Poor | | **Metastatic staging** | Limited (local/regional only) | Excellent (whole-body) | Limited | None | | **Radiation dose** | Moderate | High | None | Low | | **Availability & speed** | Widely available, rapid | Limited availability | Limited | Widely available | | **First-line status** | Yes | No (after HRCT) | No | No | **High-Yield:** HRCT can assess: 1. **Lesion characteristics:** Size, shape, margins (spiculated = malignant), density (solid vs. ground-glass), cavitation 2. **Mediastinal involvement:** Lymph node size (>1 cm short axis = suspicious), invasion 3. **Pleural involvement:** Effusion, thickening 4. **Distant lung metastases:** Bilateral nodules ## Role of Other Modalities ### PET-CT with 18F-FDG **Clinical Pearl:** PET-CT is performed **after** HRCT confirms a suspicious lesion. It is the gold standard for: - Detecting metabolically active metastases (brain, bone, liver, adrenal) - Assessing mediastinal lymph node involvement (SUVmax >2.5 = suspicious) - Whole-body staging **Mnemonic:** **PET after CT** — PET refines staging after HRCT defines the primary lesion. ### Chest MRI - Limited role in lung cancer (poor lung parenchymal detail due to motion artifact and low proton density). - Useful for assessing **superior sulcus tumors** (Pancoast) and **cardiac/mediastinal invasion**. - Not first-line for initial characterization. ### Repeat Chest X-ray - Inappropriate delay in a patient with hemoptysis and a suspicious lesion. - Does not provide adequate characterization or staging. **Warning:** Negative sputum cytology does NOT exclude lung cancer. Proceed with HRCT for definitive assessment. ## Diagnostic Algorithm ```mermaid flowchart TD A[Suspicious lung lesion on CXR]:::outcome --> B[HRCT chest with contrast]:::action B --> C{Lesion characteristics & mediastinal involvement?}:::decision C -->|Confirmed malignancy| D[PET-CT for staging]:::action C -->|Benign features| E[Follow-up imaging per Fleischner guidelines]:::action D --> F[Staging: TNM classification]:::outcome F --> G[Treatment planning]:::action ``` **Tip:** In NEET PG, remember: **HRCT is the workhorse for lung lesion characterization; PET-CT is the staging tool after HRCT confirms suspicion.**